Sorafenib (NEXAVAR) Monotherapy in Patients With Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy.
Phase of Trial: Phase II
Latest Information Update: 27 Feb 2017
At a glance
- Drugs Sorafenib (Primary)
- Indications Germ cell and embryonal neoplasms; Testicular cancer
- Focus Biomarker; Therapeutic Use
- 01 Feb 2014 Results presented at the 2014 Genitourinary Cancers Symposium.
- 10 Sep 2010 Status changed from recruiting to completed according to ISRCTN.
- 09 Nov 2008 New trial record.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History